In today’s modern world, the manufacturing of cell and gene therapies demands streamlined and proficient processes to align with the constant and rapid progress and breakthroughs in the industry. The advancements in the cell and gene therapies sector extend beyond its products alone. Upgrading technologies and adapting supply chains play an equally pivotal role. Hence, it begs the question: What is the current state of this environment, and what does the future hold?
To gain insights into manufacturing in the age of advanced therapies, The Medicine Maker consulted four experts in the field:
Josh Ludwig discusses the need to redefine manufacturing to better treat more patients with various modalities around the world and meet the growing demand of the treatments. The continued thought process around the evolution of manufacturing is, “What can we do to engineer the most simple process and tools that are also flexible?” The answer is not just-in-time manufacturing solutions. Instead, it’s tools that are ready and available today to scale up and out to serve the growing patient population.
Watch the full panel to hear key industry experts discuss redefining manufacturing.
Josh Ludwig is the Global Commercial Director for ScaleReady and has more than a decade of experience working with Wilson Wolf G-Rex bioreactors within cell and gene-modified therapy manufacturing.
